Corindus CorPath GRX Used in Live Complex Robotic-Assisted Coronary Intervention at EuroPCR 2019

May 28, 2019 — Corindus Vascular Robotics Inc. announced its CorPath GRX System was successfully used to perform a live complex robotic-assisted percutaneous coronary intervention (PCI) at the EuroPCR 2019 Conference, May 21-24 in Paris, France.

Jean Fajadet, M.D., Interventional cardiologist, PCR vice-chairman and course director of EuroPCR, performed the procedure from Clinique Pasteur in Toulouse, France. It was broadcast live to EuroPCR attendees, marking the first time a robotic procedure using CorPath GRX was performed and broadcast live in Europe. Fajadet is the co-director of the interventional cardiology unit at Clinique Pasteur, which became the first site in Europe to adopt Corindus’ most advanced vascular robotic technology when it installed the CorPath GRX System this year.

The CorPath System is the world’s only U.S. Food and Drug Administration (FDA)-cleared and CE marked robotic platform for percutaneous coronary intervention (PCI) and peripheral vascular intervention (PVI) procedures, according to the company. CorPath GRX received CE mark for neurovascular intervention in April 2019, broadening the application of the CorPath GRX System to treat all vascular beds in Europe.

“CorPath GRX offers the level of precision and control necessary to perform even the most complex PCI procedures,” said Fajadet. “The live case went exactly as planned. I was able to complete the procedure with control of all interventional devices and imaging equipment from the control room, providing my patient with high-quality care while protecting myself and the cath lab team. I am pleased to share this technology with my peers to demonstrate how far it has come, and the promising future it may provide patients.”

For more information: www.corindus.com

Related Content

$Medtronic is recalling its Pipeline Flex Embolization Device and Pipeline Flex Embolization Device with Shield Technology, which are transcatheter devices used to seal brain aneurysms. The company said there is a risk of the delivery system’s wire and tubes fracturing and breaking off when the system is being used to place, retrieve, or move the stent inside a patient.$

News | Cath Lab | September 21, 2021

Medtronic Recalls Neurovascular Pipeline Flex Embolization Devices for Risk of Fractures During Placement, Retrieval or Movement of Device

September 21, 2021 — Medtronic is recalling its Pipeline Flex Embolization Device and Pipeline Flex Embolization Devi

Feature | Cath Lab | September 14, 2021 | By Aaron Detate and Lars Thording

The Growing Need for Reprocessing in the Cardiac Cath Lab

In the electrophysiology (EP) lab, hundreds

$An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.$

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

News | Cath Lab | July 22, 2021

Quantitative Flow Ratio (QFR) Study Looks at Impact on Appropriateness of Revascularization in the PIONEER-IV Trial

July 22, 2021 — Medis Medical Imaging is partnering with CORRIB Core Lab and Sinomed in randomized clinical trial of

ast End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company's SafeCross Transseptal Radiofrequency (RF) Puncture and Steerable Balloon Introducer System. The 3-in-1 system, which includes a steerable introducer sheath with an ultra-visible positioning balloon and radiofrequency (RF) puncture dilator, aims to provide a predictable and safe solution for electrophysiology (EP) and structural heart interventions requiring left atrial access.

News | Cath Lab | July 14, 2021

FDA Clears SafeCross Transseptal RF Puncture and Steerable Balloon Introducer System

July 13, 2021 — East End Medical announced it received U.S.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor

Creating a Cardio-renal Program to Expand Patient Volume

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal fun

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021

Abbott’s New Artificial Intelligence OCT Coronary Imaging Platform Launches in Europe

May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor

SCAI 2021 Late-breaking Clinical Study Results

April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from